1.Diabetes Fact Sheets in Korea, 2020: An Appraisal of Current Status
Chan-Hee JUNG ; Jang Won SON ; Shinae KANG ; Won Jun KIM ; Hun-Sung KIM ; Hae Soon KIM ; Mihae SEO ; Hye-Jung SHIN ; Seong-Su LEE ; Su Jin JEONG ; Yongin CHO ; Seung Jin HAN ; Hyang Mi JANG ; Mira RHO ; Shinbi LEE ; Mihyun KOO ; Been YOO ; Jung-Wha MOON ; Hye Young LEE ; Jae-Seung YUN ; Sun Young KIM ; Sung Rae KIM ; In-Kyung JEONG ; Ji-Oh MOK ; Kun Ho YOON
Diabetes & Metabolism Journal 2021;45(1):1-10
Background:
This study aimed to investigate the recent prevalence, management, and comorbidities of diabetes among Korean adults aged ≥30 years by analyzing nationally representative data.
Methods:
This study used data from the Korea National Health and Nutrition Examination Survey from 2016 to 2018, and the percentage and total number of people ≥30 years of age with diabetes and impaired fasting glucose (IFG) were estimated.
Results:
In 2018, 13.8% of Korean adults aged ≥30 years had diabetes, and adults aged ≥65 years showed a prevalence rate of 28%. The prevalence of IFG was 26.9% in adults aged ≥30 years. From 2016 to 2018, 35% of the subjects with diabetes were not aware of their condition. Regarding comorbidities, 53.2% and 61.3% were obese and hypertensive, respectively, and 72% had hypercholesterolemia as defined by low-density lipoprotein cholesterol (LDL-C) ≥100 mg/dL in people with diabetes. Of the subjects with diabetes, 43.7% had both hypertension and hypercholesterolemia. With regard to glycemic control, only 28.3% reached the target level of <6.5%. Moreover, only 11.5% of subjects with diabetes met all three targets of glycosylated hemoglobin, blood pressure, and LDL-C. The percentage of energy intake from carbohydrates was higher in diabetes patients than in those without diabetes, while that from protein and fat was lower in subjects with diabetes.
Conclusion
The high prevalence and low control rate of diabetes and its comorbidities in Korean adults were confirmed. More stringent efforts are needed to improve the comprehensive management of diabetes to reduce diabetes-related morbidity and mortality.
2.The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma
Kanghyug CHOI ; Hee Yoon JANG ; Joong Mo AHN ; Sung Ho HWANG ; Jung Wha CHUNG ; Yun Suk CHOI ; Jin-Wook KIM ; Eun Sun JANG ; Gwang Hyeon CHOI ; Sook-Hyang JEONG
Clinical and Molecular Hepatology 2020;26(4):492-505
Background/Aims:
The role of serum myokine levels in sarcopenia and the outcome of hepatocellular carcinoma (HCC) patients are not clear. This study investigated the serum levels of myostatin, follistatin, and interleukin-6 (IL-6) in HCC patients and their association with sarcopenia and survival.
Methods:
Using prospectively collected pretreatment samples from 238 HCC patients in a hospital from 2012 to 2015, the serum levels of 3 myokines were determined and compared to 50 samples from age and sex-matched healthy controls. Sarcopenia was evaluated using the psoas muscle index (PMI) measured at the third lumbar level in the computed tomography, and clinical data were collected until 2017.
Results:
The median levels of the 3 myokines for the male and female HCC patients were as follow: myostatin (3,979.3 and 2,976.3 pg/mL), follistatin (2,118.5 and 2,174.6 pg/mL), and IL-6 (2.5 and 2.7 pg/mL), respectively. Those in the HCC patients were all significantly higher than in the healthy controls. In the HCC patient, the median PMI was 4.43 (males) and 2.17 cm2/m2 (females) with a sarcopenic prevalence of 56.4%. The serum levels of myostatin, IL-6 and follistatin in the HCC patients showed a positive, negative, and no correlation with PMI, respectively. The serum follistatin level was an independent factor for poor survival in HCC patients.
Conclusions
The serum levels of myostatin, follistatin, and IL-6 and their correlation with sarcopenia and survival were presented in HCC patients for the first time. The role of the serum follistatin level as a poor prognostic biomarker warrants further study.
3.Surveillance Rate and its Impact on Survival of Hepatocellular Carcinoma Patients in South Korea: A Cohort Study
Sanghyuk IM ; Eun Sun JANG ; Ju Hyun LEE ; Chung Seop LEE ; Beom Hee KIM ; Jung Wha CHUNG ; Jin Wook KIM ; Sook Hyang JEONG
Cancer Research and Treatment 2019;51(4):1357-1369
PURPOSE: Though regular surveillance of hepatocellular carcinoma (HCC) for high-risk patients is widely recommended, its rate and effectiveness are not clear. The aim of this study is to investigate the actual rate of HCC surveillance and its related factors and to clarify its impact on survival in a Korean HCC cohort. MATERIALS AND METHODS: From 2012 to 2015, 319 newly diagnosed HCC patients were prospectively enrolled at a tertiary hospital. Patient interviews based on a structured questionnaire survey were conducted. Surveillance was defined as liver imaging test ≥ 2 times with at least 3-month interval within 2 years prior to HCC diagnosis. RESULTS: Surveillance rate was 39.8%. Of the HCC patients with high-risk factors, only 182 (57.1%) had knowledge for the need for regular surveillance, and 141 (44.2%) had the accurate information about the method (ultrasound-based study). Surveillance group showed a higher proportion of early HCC (p < 0.001) and a longer overall survival (p < 0.001) compared to non-surveillance group. The multivariable Cox regression analysis indicated Child-Pugh class A, history of anti-viral therapy, low serum α-fetoprotein level, non-advanced Barcelona Clinic Liver Cancer stage as independent predictors of overall survival, while regular surveillance was not (p=0.436). CONCLUSION: Less than half of the newly diagnosed Korean HCC patients were under surveillance and the accurate perception for the need of HCC surveillance was insufficient. Of those under surveillance, most patients were diagnosed with early stage HCC, which led to the improved survival. Comprehensive efforts to optimize the surveillance program for the target population are warranted.
Carcinoma, Hepatocellular
;
Cohort Studies
;
Diagnosis
;
Health Services Needs and Demand
;
Humans
;
Korea
;
Liver
;
Liver Cirrhosis
;
Liver Neoplasms
;
Mass Screening
;
Methods
;
Prospective Studies
;
Tertiary Care Centers
4.Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis
Beom Hee KIM ; Jung Wha CHUNG ; Chung Seop LEE ; Eun Sun JANG ; Sook Hyang JEONG ; Nayoung KIM ; Jin Wook KIM
The Korean Journal of Internal Medicine 2019;34(6):1233-1243
BACKGROUND/AIMS:
Non-selective β-blockers (NSBBs) are used for primary prevention of esophageal variceal hemorrhage (VH) in patients with portal hypertension, but a significant number of patients develop VH while on NSBB therapy. In this study, we sought to determine whether liver volume can predict the risk of primary prophylaxis failure in cirrhotic patients on NSBB therapy.
METHODS:
A retrospective cohort of 309 patients on prophylactic propranolol was analyzed. Liver volume was measured in portal venous phase images of multidetector computed tomography. Predictors of VH were assessed using a Cox proportional hazards model with competing-risks analysis. A nomogram was developed for estimation of the risk of primary prophylaxis failure.
RESULTS:
During a median follow-up of 36 months, 37 patients on propranolol developed VH. Liver volume index, the ratio of measured-to-expected liver volume, was an independent predictor of VH (adjusted hazard ratio [HR], 2.70; 95% confidence interval [CI], 1.37 to 5.33; p = 0.004) as were the presence of large varices and the absence of ascites. A nomogram-based volume score of > 0.6 was predictive of prophylaxis failure (HR, 7.54; 95% CI, 2.88 to 19.73; p < 0.001). Time-dependent receiver operating characteristic curve analysis revealed that a nomogram-based risk score had significantly better discriminatory power than the North Italian Endoscopy Club index in predicting prophylaxis failure at 6 and 8 years.
CONCLUSIONS
Liver volume index is an independent predictor of first VH and a nomogram-based volume score stratifies the VH risk in cirrhotic patients on propranolol prophylaxis.
5.Prevalence and Incidence of Depression during Interferon-Based Antiviral Therapy in Chronic Hepatitis C Patients in the Republic of Korea.
Joo Yeong BAEG ; In Hee KIM ; Seung Young SEO ; Young Seok KIM ; Eun Uk JUNG ; Junhyeon CHO ; Jung Wha CHUNG ; Eun Sun JANG ; Jin Wook KIM ; Sook Hyang JEONG
Gut and Liver 2017;11(3):426-433
BACKGROUND/AIMS: The association between depression and chronic hepatitis C virus (HCV) infection or pegylated interferon α and ribavirin therapy (PR therapy) has not been extensively studied in Korea. We aimed to clarify the prevalence of depression and its incidence during PR therapy in chronic hepatitis C (CHC) patients. METHODS: In this prospective, multicenter study, 114 CHC patients were screened for depression using two self-reported scales, the Beck Depression Inventory-I (BDI-I) and the Hospital Anxiety and Depression scale (HADS). The incidence of depression during PR therapy was evaluated in 62 patients who underwent PR therapy during the study period. RESULTS: The prevalence of baseline depression was 17.5% according to the BDI-I score ≥10 criterion and 4.4% according to the HADS-D score ≥8 criterion in the 114 CHC patients, and it was significantly associated with an unmarried state. During PR therapy, depression developed in 34.6% according to the BDI-I scale and 29.5% according to the HADS-D, which negatively affected sustained virologic response (SVR). CONCLUSIONS: The prevalence of depression in Korean CHC patients appears to be low compared to that in Western patients; however, its incidence during PR therapy (approximately 30%) was similar to that of other populations, which led to a lower SVR rate. Active screening and multidisciplinary management of depression during PR therapy is warranted.
Anxiety
;
Depression*
;
Hepacivirus
;
Hepatitis C, Chronic*
;
Hepatitis, Chronic*
;
Humans
;
Incidence*
;
Interferons
;
Korea
;
Mass Screening
;
Prevalence*
;
Prospective Studies
;
Republic of Korea*
;
Ribavirin
;
Single Person
;
Weights and Measures
6.Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study.
Gi Hyun KIM ; Jung Wha CHUNG ; Jong Ho LEE ; Kyeong Sam OK ; Eun Sun JANG ; Jaihwan KIM ; Cheol Min SHIN ; Young Soo PARK ; Jin Hyeok HWANG ; Sook Hyang JEONG ; Nayoung KIM ; Dong Ho LEE ; Jin Wook KIM
Clinical and Molecular Hepatology 2015;21(4):379-386
BACKGROUND/AIMS: Vitamin E improves the biochemical profiles and liver histology in nonalcoholic steatohepatitis, but the role of vitamin E is not clearly defined in the management of nonalcoholic fatty liver disease (NAFLD) which includes both simple steatosis and steatohepatitis. Co-morbid metabolic syndrome increases the probability of steatohepatitis in NAFLD. In this study, we aimed to determine the short-term effects of vitamin E and off-treatment durability of response in a propensity-score matched cohort of NAFLD patients with metabolic syndrome. METHODS: A retrospective cohort was constructed by retrieving 526 consecutive NAFLD patients from the electronic medical record data warehouse of a tertiary referral hospital in South Korea. Among them, 335 patients (63.7%) had metabolic syndrome and were eligible for vitamin E therapy. In order to assess the effect of vitamin E, propensity score matching was used by matching covariates between control patients (n=250) and patients who received vitamin E (n=85). RESULTS: The PS-matched vitamin E group (n=58) and control group (n=58) exhibited similar baseline metabolic profiles. After 6 months of vitamin E therapy, the mean ALT levels decreased significantly compared to PS-matched control (P<0.01). The changes in metabolic profiles (body weight, lipid and glucose levels) did not differ between control and vitamin E groups during the study period. CONCLUSIONS: Short-term vitamin E treatment significantly reduces ALT levels in NAFLD patients with metabolic syndrome, but metabolic profiles are not affected by vitamin E.
Adult
;
Aged
;
Alanine Transaminase/blood
;
Aspartate Aminotransferases/blood
;
Body Weight
;
Cohort Studies
;
Female
;
Humans
;
Lipoproteins, HDL/blood
;
Lipoproteins, LDL/blood
;
Liver/pathology
;
Male
;
Metabolic Syndrome X/*complications/diagnosis/drug therapy
;
Middle Aged
;
Non-alcoholic Fatty Liver Disease/*complications/diagnosis/*drug therapy
;
Propensity Score
;
Republic of Korea
;
Retrospective Studies
;
Vitamin E/*therapeutic use
7.Current Status of Management in Type 2 Diabetes Mellitus at General Hospitals in South Korea.
Jin Hee JUNG ; Jung Hwa LEE ; Jin Won NOH ; Jeong Eun PARK ; Hee Sook KIM ; Joo Wha YOO ; Bok Rye SONG ; Jeong rim LEE ; Myeong Hee HONG ; Hyang Mi JANG ; Young NA ; Hyun Joo LEE ; Jeong Mi LEE ; Yang Gyo KANG ; Sun Young KIM ; Kang Hee SIM
Diabetes & Metabolism Journal 2015;39(4):307-315
BACKGROUND: In Korea, the prevalence, complications, and mortality rate of diabetes are rapidly increasing. However, investigations on the actual condition of diabetes management are very limited due to lack of nation-wide research or multicenter study. Hence, we have minutely inquired the current status of diabetes management and achievement of glucose target goal in general hospital offering education program. That way, we are able to furnish data for policy making of diabetes education and draw up guideline which may allow us to reduce the morbidity and mortality of diabetes. METHODS: The subjects consisted of 2,610 patients with type 2 diabetes who visited the 13 general hospital in Seoul or Gyeonggi region from March 19 to May 29, 2013. General characteristics, associated diseases, complications, and management status were investigated. RESULTS: The mean age was 61.0+/-11.6 years, body mass index was 25.0+/-3.3 kg/m2, and family history of diabetes was 50.5%. The mean duration of diabetes was 10.7+/-7.9 years and 53% received education about diabetes. The prevalence of hypertension and dyslipidemia were 59.2% and 65.5%, respectively, and 18.3% of the subjects were accompanied by liver disease. Diabetic retinopathy appeared in 31.6%, nephropathy in 28.1%, and neuropathy in 19.9% of the subjects. The mean glycosylated hemoglobin (HbA1c) level was 7.3%+/-1.3% and the achieving rate based on Korean Diabetes Association guideline (HbA1c <6.5%) was 24.8%, blood pressure (130/80 mm Hg or less) was 49.4%, and low density lipoprotein cholesterol (<100 mg/dL) was 63.6%. The reaching rate to the target level in four parameters (blood glucose, blood pressure, lipids, and body weight) was 7.8%. CONCLUSION: The blood glucose control rate was lower than other parameters, and the implementation rate of diabetes education was only 53%. Thus more appropriate glucose control and systematic diabetes education are imperative.
Blood Glucose
;
Blood Pressure
;
Body Mass Index
;
Cholesterol, LDL
;
Diabetes Mellitus, Type 2*
;
Diabetic Retinopathy
;
Dyslipidemias
;
Education
;
Glucose
;
Gyeonggi-do
;
Hemoglobin A, Glycosylated
;
Hospitals, General*
;
Humans
;
Hypertension
;
Korea*
;
Liver Diseases
;
Mortality
;
Policy Making
;
Prevalence
;
Seoul
8.Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis.
Jung Wha CHUNG ; Gi Hyun KIM ; Jong Ho LEE ; Kyeong Sam OK ; Eun Sun JANG ; Sook Hyang JEONG ; Jin Wook KIM
Clinical and Molecular Hepatology 2014;20(4):384-391
BACKGROUND/AIMS: Portal-vein thrombosis (PVT) develops in 10-25% of cirrhotic patients and may aggravate portal hypertension. There are few data regarding the effects of anticoagulation on nonmalignant PVT in liver cirrhosis. The aim of this study was to elucidate the safety, efficacy, and predictors of response to anticoagulation therapy in cirrhotic patients. METHODS: Patients with liver cirrhosis and nonmalignant PVT were identified by a hospital electronic medical record system (called BESTCARE). Patients with malignant PVT, Budd-Chiari syndrome, underlying primary hematologic disorders, or preexisting extrahepatic thrombosis were excluded from the analysis. Patients were divided into two groups (treatment and nontreatment), and propensity score matching analysis was performed to identify control patients. The sizes of the thrombus and spleen were evaluated using multidetector computed tomography. RESULTS: Twenty-eight patients were enrolled in this study between 2003 and 2014: 14 patients who received warfarin for nonmalignant PVT and 14 patients who received no anticoagulation. After 112 days of treatment, 11 patients exhibited significantly higher response rates (complete in 6 and partial in 5) compared to the control patients, with decreases in thrombus size of >30%. Compared to nonresponders, the 11 responders were older, and had a thinner spleen and fewer episodes of previous endoscopic variceal ligations, whereas pretreatment liver function and changes in prothrombin time after anticoagulation did not differ significantly between the two groups. Two patients died after warfarin therapy, but the causes of death were not related to anticoagulation. CONCLUSIONS: Warfarin can be safely administered to cirrhotic patients with nonmalignant PVT. The presence of preexisting portal hypertension is a predictor of nonresponse to anticoagulation.
Aged
;
Anticoagulants/*therapeutic use
;
Female
;
Humans
;
Liver Cirrhosis/complications/*diagnosis
;
Male
;
Middle Aged
;
Portal Vein
;
Propensity Score
;
Severity of Illness Index
;
Tomography, X-Ray Computed
;
Venous Thrombosis/complications/*drug therapy/pathology
;
Warfarin/therapeutic use
9.A Case of Tuberculous Prostatitis with Abscess.
Seung Whan DOO ; Jae Heon KIM ; Won Jae YANG ; Soon Im KIM ; Dong Wha LEE ; Seong Sook HONG ; Yun Seob SONG
The World Journal of Men's Health 2012;30(2):138-140
We present a case of acute prostatitis with abscess. The patient had undergone intravesical bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer. A prostate biopsy demonstrated tuberculous prostatitis with abscess. This case illustrates that when bladder cancer is treated with BCG, a tuberculous prostate abscess can develop.
Abscess
;
Bacillus
;
Biopsy
;
Humans
;
Immunotherapy
;
Mycobacterium bovis
;
Prostate
;
Prostatitis
;
Tuberculosis
;
Urinary Bladder Neoplasms
10.WHO Classification of Malignant Lymphomas in Korea: Report of the Third Nationwide Study.
Jin Man KIM ; Young Hyeh KO ; Seung Sook LEE ; Jooryung HUH ; Chang Suk KANG ; Chul Woo KIM ; Yun Kyung KANG ; Jai Hyang GO ; Min Kyung KIM ; Wan Seop KIM ; Yoon Jung KIM ; Hyun Jung KIM ; Hee Kyung KIM ; Jong Hee NAM ; Hyung Bae MOON ; Chan Kum PARK ; Tae In PARK ; Young Ha OH ; Dong Wha LEE ; Jong Sil LEE ; Juhie LEE ; Hyekyung LEE ; Sung Chul LIM ; Kyu Yun JANG ; Hee Kyung CHANG ; Yoon Kyung JEON ; Hye Ra JUNG ; Min Sun CHO ; Hee Jeong CHA ; Suk Jin CHOI ; Jae Ho HAN ; Sook Hee HONG ; Insun KIM
Korean Journal of Pathology 2011;45(3):254-260
BACKGROUND: The aim of study was to determine the relative frequency of malignant lymphoma according to World Health Organization (WHO) classification in Korea. METHODS: A total of 3,998 cases diagnosed at 31 institutes between 2005 and 2006 were enrolled. Information including age, gender, pathologic diagnosis, site of involvement and immunophenotypes were obtained. RESULTS: The relative frequency of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) was 95.4% and 4.6%, respectively. B-cell lymphomas accounted for 77.6% of all NHL, while T/natural killer (T/NK)-cell lymphomas accounted for 22.4%. The most frequent subtypes of NHL were diffuse large B-cell lymphoma (42.7%), extranodal marginal zone B-cell lymphoma (MZBCL) of mucosa-associated lymphoid tissue (19.0%), NK/T-cell lymphoma (6.3%) and peripheral T-cell lymphoma (PTCL), unspecified (6.3%), in decreasing order. The relative frequency of HL was nodular sclerosis (47.4%), mixed cellularity (30.6%), and nodular lymphocyte predominant (12.1%) subtypes. Compared with a previous study in 1998, increase in gastric MZBCL and nodular sclerosis HL, and slight decrease of follicular lymphoma, PTCL, and NK/T-cell lymphoma were observed. CONCLUSIONS: Korea had lower rates of HL and follicular lymphoma, and higher rates of extranodal NHL, extranodal MZBCL, and NK/T-cell lymphoma of nasal type compared with Western countries. Changes in the relative frequency of lymphoma subtypes are likely ascribed to refined diagnostic criteria and a change in national health care policy.
Academies and Institutes
;
Delivery of Health Care
;
Hodgkin Disease
;
Korea
;
Lymphocytes
;
Lymphoid Tissue
;
Lymphoma
;
Lymphoma, B-Cell
;
Lymphoma, B-Cell, Marginal Zone
;
Lymphoma, Follicular
;
Lymphoma, Non-Hodgkin
;
Lymphoma, T-Cell, Peripheral
;
Sclerosis
;
World Health Organization

Result Analysis
Print
Save
E-mail